Renaissance Capital logo

FibroBiologics Priced, Nasdaq: FBLG

Phase 1 biotech developing fibroblast-based therapies for chronic diseases.

Industry: Health Care

Latest Trade: $2.41 0.00 (0.0%)

First Day Return: +263.8%

Return from IPO: -69.9%

Industry: Health Care

We are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. At present, our novel manufacturing process entails collecting excess tissue from surgical procedures and using the allogeneic fibroblasts to grow a cell bank for use in our procedures. Our most advanced product candidates are CybroCell™ and CYMS101. CybroCell™ is an allogeneic fibroblast cell-based therapy for degenerative disc disease and is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). We are developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat MS. Since our spinoff from FibroGenesis in April 2021, our operations have included business planning, hiring personnel, raising capital, building our intellectual property portfolio and performing research and development on our product candidates and our fibroblast technology, leveraging the clinical benefits of fibroblasts as the basis of our cell therapy platform.
more less
IPO Data
IPO File Date 11/07/2023
Offer Price $8.00
Price Range $8.00 - $8.00
Offer Shares (mm) 4.8
Deal Size ($mm) $0
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/31/2024
Offer Price $8.00
Price Range $8.00 - $8.00
Offer Shares (mm) 4.8
Deal Size ($mm) $0
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Maxim Group LLC
Company Data
Headquarters Houston, TX, United States
Founded 2006
Employees at IPO 8
Website www.fibrobiologics.com

FibroBiologics (FBLG) Performance